Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats
Open Access
- 31 August 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 146 (2), 278-286
- https://doi.org/10.1111/j.1365-2249.2006.03198.x
Abstract
Summary: Myasthenia gravis (MG) is a debilitating and potentially fatal neuromuscular disease characterized by the generation of autoantibodies reactive with nicotinic acetylcholine receptors (AChR) that cause loss of AChR from the neuromuscular endplate with resultant failure of neuromuscular transmission. A role for complement (C) in the pathology of human MG has been suggested based upon identification of C activation products in plasma and deposited at the endplate in MG. In the rat model, experimental autoimmune MG (EAMG), C depletion or inhibition restricts clinical disease, further implicating C in pathology. The mechanisms by which C activation drives pathology in MG and EAMG are unclear. Here we provide further evidence implicating C and specifically the membrane attack complex (MAC) in the Lewis rat passive EAMG model of MG. Rats deficient in C6, an essential component of the MAC, were resistant to disease induction and endplate destruction was reduced markedly compared to C6-sufficient controls. After reconstitution with C6, disease severity and endplate destruction in the C6-deficient rats was equivalent to that in controls. The data confirm the essential role of the MAC in the destruction of the endplate in EAMG and raise the prospect of specific MAC inhibition as an alternative therapy in MG patients resistant to conventional treatments.Keywords
This publication has 31 references indexed in Scilit:
- Pexelizumab – a C5 complement inhibitor for use in both acute myocardial infarction and cardiac surgery with cardiopulmonary bypassExpert Opinion on Biological Therapy, 2005
- The role of complement in myasthenia gravis: serological evidence of complement consumption in vivoJournal of Neuroimmunology, 2005
- Tailoring anti-complement therapeuticsBiochemical Society Transactions, 2002
- Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravisJournal of Neuroimmunology, 1996
- Active Heymann nephritis in complement component C6 deficient ratsKidney International, 1995
- Hereditary C6 deficiency in a strain of PVG/c ratsClinical and Experimental Immunology, 1994
- An electrophysiological study of the effects of myasthenia gravis sera and complement on rat isolated muscle fibresJournal of Neuroimmunology, 1993
- Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptorJournal of Neuroimmunology, 1987
- Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.The Journal of Experimental Medicine, 1976
- Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis.The Journal of Experimental Medicine, 1976